# Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

> **NCT04529850** · PHASE2 · COMPLETED · sponsor: **Galera Therapeutics, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Head and Neck Cancer
- Oral Mucositis

## Interventions

- **DRUG:** Drug: GC4419
- **RADIATION:** Intensity-modulated radiation therapy (IMRT)
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04529850
- **Lead sponsor:** Galera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-30
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04529850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04529850, "Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04529850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*